Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04921644
Other study ID # LIFT project
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 20, 2021
Est. completion date February 28, 2024

Study information

Verified date November 2022
Source German Cancer Research Center
Contact Marlena Milzer
Phone +49 6221/42 2207
Email marlena.milzer@dkfz-heidelberg.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The LIFT project aims to thoroughly investigate the current status of health care in Germany regarding cancer-related fatigue from the institutional, professionals' and patients' perspective.


Description:

The LIFT project aims to thoroughly investigate the current status of health care in Germany regarding fatigue from the institutional, professionals', and patients' perspective. With a multimodal approach including a comprehensive assessment of fatigue management and support offered by different institutions (uncertified hospitals, uncertified oncological practices, counselling units, certified cancer centers; n=350), a survey and qualitative interviews among practicing physicians ("Niedergelassene Ärzte"), hospital physicians, practicing psychotherapists with psycho-oncological focus, psycho-oncologists at hospitals, nurses at certified cancer centers and nurses at other hospitals (n=420), and a longitudinal clinical study among cancer patients (n=1400) as well as two focus groups with patient representatives (each n=6), the characteristics, patterns, and potential effects or shortcomings of the current fatigue management will be investigated. Furthermore, factors associated with patients' and health care professionals' knowledge about fatigue will be examined. Concerning the longitudinal clinical study assessing the patients' perspective, online or paper-based questionnaires on socio-demographic, clinical and patient reported outcomes will be sent to the patients 6,9,12 and 24 months after diagnosis. Moreover, detailed data on screening, diagnosis and counseling as well as therapies offered and administered to reduce fatigue will be surveyed, as well as the patients' state of knowledge, perception and prevailing needs regarding fatigue. Tumor and cancer therapy data will be extracted from the Epidemiological Cancer Registry. The results of the LIFT project shall provide a basis to identify and overcome shortcomings in the actual fatigue management in Germany, and, to eventually ameliorate this severe burden in cancer patients and survivors.


Recruitment information / eligibility

Status Recruiting
Enrollment 1400
Est. completion date February 28, 2024
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - = 18 years of age - Newly diagnosed with a primary tumor of one of the following malignant neoplasms: colon (C18), rectum (C19-20), liver (C22), pancreas (C25), lung (C33-34), malignant melanoma (C43), breast (C50, only female), cervix (C53), endometrium (C54.1), ovaries (C56), prostate (C61), kidney (C64), bladder (C67), thyroid gland (C73), non-Hodgkin lymphoma (C82-88), leukemia (C91-C95) - Having received or receiving at enrolment at least one of the following treatments: chemotherapy, radiotherapy, hormone therapy, targeted or immune therapy - Able to understand and follow the study protocol Exclusion Criteria: - Carcinoma in situ - Any additional malignant or unclear neoplasm before or since time of diagnosis of the considered primary tumor, except unspecified neoplasm of skin (C44)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany German Cancer Research Center Heidelberg

Sponsors (4)

Lead Sponsor Collaborator
German Cancer Research Center Baden-Württemberg Cancer Registry, German Research Foundation, Wuerzburg University Hospital

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fatigue severity assessed by EORTC QLQ-FA12 (European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire). The items are rated on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much) with higher scores meaning a higher level of fatigue. 6 months after diagnosis to 2 years post-diagnosis
Primary Impact of fatigue assessed by the Brief Fatigue Inventory (BFI). The BFI consists of an 11-point numerical rating scale ranging from 0 (no fatigue) to 10 (as bad as you can imagine) with higher scores signifying higher intensity and impairment. 6 months after diagnosis to 2 years post-diagnosis
Primary State of fatigue management Questionnaire assessing the adherence to the National Comprehensive Cancer Network (NCCN) guidelines regarding management of cancer-related fatigue. 6 months after diagnosis to 2 years post-diagnosis
Primary Knowledge, attitudes and beliefs regarding cancer-related fatigue Questionnaire assessing knowledge, attitudes and beliefs regarding cancer-related fatigue. The knowledge score consists of fatigue-related statements that should be rated as either right, wrong, or "dont know". The attitudes scale is composed of statements that should be rated on a 4-point likert scale. Higher scores indicate a greater agreement to the particular statement. 6 months after diagnosis to 2 years post-diagnosis
Secondary Quality of life functions and symptoms assessed by EORTC QLQ-C30 and 5 additional items derived according to the EORTC scoring manual assessing symptoms of fever, hot flashes, night sweat, polyneuropathy and distress of dependents caused by the diagnosis are added. The items are rated on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much). A higher score corresponds to a higher level of symptoms/problems. 6 months after diagnosis to 2 years post-diagnosis
Secondary Sleep problems assessed by Pittsburgh Sleep Quality Index (PSQI). The PSQI consists of open and closed questions regarding characteristics of sleep and sleep quality. Some items are rated on a 4-point likert scale with higher scores meaning more sleep problems. 6 months after diagnosis to 2 years post-diagnosis
Secondary Depression assessed by Patient Health Questionnaire (PHQ-9). The items are rated on a 4-point scale ranging from 0 (not at all) to 3 (most of the time). A sum score is calculated, with higher scores meaning a higher level of depressive symptoms. 6 months after diagnosis to 24 months post-diagnosis
Secondary Body mass index calculated from weight and height 6 months, 12 months and 24 months post-diagnosis
Secondary Total physical activity assessed by a questionnaire regarding walking, cycling and exercise behavior 6 months, 12 months and 24 months post-diagnosis
Secondary Return to work assessed by questions regarding occupational issues 6 months, 12 months and 24 months post-diagnosis
Secondary Anxiety assessed by the Generalized Anxiety Disorder Questionnaire (GAD-7). The items are rated on a 4-point scale ranging from 0 (not at all) to 3 (most of the time). A sum score (ranging from 0 to 21) is calculated, with higher scores meaning a higher level of symptomatology. assessed 6 months after diagnosis to 24 months after diagnosis
Secondary Supportive Care Needs assessed by the Supportive Care Needs Survey (SCNS-SF-34). The scale ranges from 1 (not applicable) to 5 (high need) with higher scores meaning a higher need of support. assessed at t2 9 months post-diagnosis
Secondary Social Support assessed by the Illness-specific Social Support Scale (ISSS, German Version) among cancer patients. The 8 items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (always). Sum scores for the items 1,3,6 and 8 (positive support) as well as for the items 2,4,5 and 7 (detrimental interaction) are calculated with higher scores meaning higher levels of positive support and detrimental interaction respectively. at t1 (6 months post-diagnosis) and t3 (12 months post-diagnosis)
Secondary Loneliness assessed by three items of the University of California, Los Angeles (UCLA)-loneliness-scale. The response categories are 1 (hardly ever), 2 (some of the time) and 3(often). A sum score is calculated with higher scores meaning a higher level of loneliness. at t1 (6 months post-diagnosis) and t4 (24 months post-diagnosis)
Secondary Resilience assessed by the Brief Resilience Scale (BRS). The six items are rated on a 5-point Likert-scale ranging from 1 (strongly disagree) to 5 (strongly agree). After reversing the coding of inverted items 2,4 and 6, the mean of the six items is calculated with higher scores meaning a higher level of resilience. assessed at t1 6 months post-diagnosis
Secondary Patient Activation assessed by the Patient Activation Measure (PAM-13). Patients are supposed to rate their level of agreement to 13 statements on a 4-point-scale. A higher score corresponds to a higher level of patient activation. at t2 (9 months post-diagnosis)
Secondary Posttraumatic growth assessed by Posttraumatic Growth Inventory (PTGI). The items are rated on a 6-point Likert scale ranging from 1 (not at all) to 6 (very strongly) with higher scores indicating a higher level of posttraumatic growth. at t4 (24 months post-diagnosis)
See also
  Status Clinical Trial Phase
Recruiting NCT05428527 - Real-world Clinical Benefit Evaluation in Breast Cancer Patients With Pharmaceutical Interventions for Cancer-related Fatigue
Completed NCT04563013 - Study of the Effects of Transcutaneous Vagus Nerve Stimulation on Cancer Patients N/A
Recruiting NCT05613465 - Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo N/A
Recruiting NCT05448573 - A Longitudinal Study to Investigate and Develop a Patient-centered and Effective Fatigue Screening
Completed NCT03897556 - Effect of High-Dose Guarana And Cancer-Related Fatigue N/A
Recruiting NCT04147312 - Fufang E'Jiao Jiang Intervening Cancer-related Fatigue N/A
Active, not recruiting NCT03318224 - Fatigue Prevalence, Severity, and State of Treatment in Germany
Completed NCT01720550 - PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care Phase 4
Not yet recruiting NCT06381557 - Cancer-related Fatigue in Patients With Breast Cancer Treatment With Zhengyuan Capsules Phase 4
Completed NCT05009693 - Effect of White Light on Fatigue Levels in Patients With Gynecological Cancer N/A
Completed NCT03049384 - Tailored Exercise Interventions to Reduce Fatigue in Cancer Survivors N/A
Withdrawn NCT03211273 - Longitudinal Investigation of Cancer-related Fatigue
Recruiting NCT02661308 - Reducing Cancer Side-effects With Systematic Light Exposure N/A
Completed NCT02740959 - Effects of PG2 on Fatigue-Related Symptom Clusters N/A
Completed NCT03314805 - PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy Phase 2
Completed NCT03553355 - Effects of Infrared Laser Moxibustion on Cancer-related Fatigue in Breast Cancer Patients N/A
Recruiting NCT05440227 - PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients Phase 2
Enrolling by invitation NCT01228773 - The Efficacy of Health Navigation® for Cancer-Related Fatigue in Cancer Survivors Phase 2
Not yet recruiting NCT04947969 - Clinical Effect of Laser Acupuncture on Improving Cancer-related Fatigue N/A
Not yet recruiting NCT00552552 - Development and Evaluation of a Cancer-Related Fatigue Patient Education Program N/A